Semaglutide: Research overview, identity, and laboratory handling guide

Long-acting GLP-1 receptor agonist analogue studied in vitro for incretin signaling, β-cell line response, and metabolic-pathway research. ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What Semaglutide is in published research

Semaglutide is a GLP-1(7-37) analogue with Aib substitution at position 8, Arg34→Lys, and a γ-Glu-2×OEG-C18 di-acid acylation on Lys-26. The substitution at position 8 confers in vitro stability against DPP-IV; the acylation extends in vitro half-life in published research. Common assay use covers receptor binding, β-cell line cAMP signaling, and metabolic-pathway studies in cell and animal model literature.

Each lot is provided with ≥99% HPLC purity and MS identity verification covering backbone and acyl modification. Net peptide content is reported on the CoA. Labs running cross-analogue work commonly compare the acyl-mass delta against liraglutide and tirzepatide on the same assay plate; that data is filed by SKU.

Hold lyophilized vials at -20 °C sealed and protected from light. Reconstitute in lab-grade slightly alkaline buffer. Aliquot before freezing to limit freeze/thaw.

CoA covers identity (MS), purity (HPLC), and net peptide content. Batch records by lot are filed against the SKU for procurement and compliance review.

The material class "GLP-1 receptor analogue (research)" helps procurement teams group Semaglutide with related reference peptides during comparative studies.

Sequence and identity

Semaglutide identity on the catalog: Common name: Semaglutide; Origin: GLP-1(7-37) analogue with C-18 di-acid acylation on Lys-26; Molecular formula: C187H291N45O59; Molecular weight: 4,113.58 g/mol; Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Solubility: Soluble in slightly alkaline lab buffers. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on Semaglutide is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates Semaglutide pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same Semaglutide SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for Semaglutide at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for Semaglutide working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized Semaglutide sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in Semaglutide, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing Semaglutide with adjacent catalog references often evaluate the following SKUs in parallel plates:

Liraglutide (liraglutide) — compare identity table and CoA fields side by side.

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.